ABS-201 in Androgenetic Alopecia

Phase 1/2 trial primarily assesses safety; TAHC is secondary. Novel anti-PRLR antibody has no clinical proof in AGA. Small uncontrolled trial, high risk of no numerical improvement or non-reporting by Dec 2026. Estimated 5% chance of reporting positive TAHC.

Novel anti-PRLR antibody in AGA, Phase 1/2 primarily safety, small sample likely underpowered for TAHC. Early-stage trials for new mechanisms rarely show clear efficacy. Tight timeline to report by Dec 2026. Low probability of numerical TAHC improvement.

Phase 1/2 trial still recruiting with primary completion Dec 31, 2026. Reporting TAHC data by that date is unlikely due to data lock, analysis, and disclosure timelines. Small chance of early phase 1 data, but overall low probability.

Early Phase 1/2 trial primarily for safety; TAHC is exploratory. Small sample, not powered for efficacy. Anti-PRLR mechanism unproven in AGA. Chance of any numerical improvement by Dec 2026 is low (~5%), but non-zero due to possible random variation or early signal.

Phase 1/2 safety trial; TAHC is a secondary endpoint. Novel anti-PRLR antibody, unproven in AGA. Trial still recruiting, only 175 days to primary completion; unlikely to have robust efficacy data by Dec 2026. High risk of no numerical improvement reported.

Phase 1/2 trial of novel anti-PRLR antibody in AGA; primary endpoint is safety, TAHC is exploratory. Early-stage, small sample, high uncertainty; base rate for such programs showing numerical improvement is low (~5%).

Phase 1/2 trial with safety primary endpoint; TAHC is exploratory. Small sample, no prior efficacy data. Novel anti-PRLR mechanism has high uncertainty. Base rate for numerical improvement in early-phase AGA trials is low (~15%). Operational risk of timely completion exists but reporting by Dec 2026 is plausible.

Phase 1/2 safety trial, small sample, TAHC exploratory. Unlikely to report numerical improvement data by Dec 31, 2026 (primary completion date). Low prior probability of efficacy in AGA for a novel anti-PRLR antibody.

Phase 1/2 trial with safety primary endpoint; TAHC is exploratory. No prior efficacy data, novel mechanism, small sample likely, and reporting by Dec 2026 uncertain. Numerical improvement unlikely.

Phase 1/2 safety study, anti-PRLR antibody, unproven mechanism. Small sample, still recruiting, primary completion Dec 31, 2026, leaving no time to report data by that date. Numerical TAHC improvement possible but unlikely given early stage and tight timeline. Probability ~5%.

Phase 1/2 trial of novel anti-PRLR antibody in AGA; primarily safety, no prior efficacy data. Small sample, tight timeline (177 days to data). Numerical TAHC improvement possible but low probability given high failure rate of early-stage hair loss therapies and unproven mechanism.

Phase 1/2 trial primarily for safety; no prior human efficacy data for anti-PRLR in AGA. Numerical improvement possible but far from certain given early stage, small sample, and novel mechanism. Base rate for Phase 1/2 success is low.

Phase 1/2 trial primarily assesses safety, not efficacy. No prior clinical data on anti-PRLR in AGA. TAHC is a secondary endpoint, and reporting by Dec 2026 is uncertain given recruitment status. Low probability of numerical improvement.

Phase 1/2 trial primarily assessing safety, small sample size, novel anti-PRLR mechanism with no prior TAHC data, high likelihood of failing to show numerical improvement in TAHC by Dec 2026.

Phase 1/2 trial with novel anti-PRLR antibody, small sample, safety-focused. Numerical TAHC improvement is a low bar but high risk of no effect or non-reporting. Market price overestimates success.

Phase 1/2 trial with primary safety endpoint; TAHC is secondary. Tight timeline (6 months to primary completion) limits ability to collect and report meaningful hair count data. Novel anti-PRLR mechanism unproven in AGA. Likely underpowered and may not show numerical improvement, or data may not be reported by Dec 31, 2026.

Phase 1/2 trial primarily for safety; TAHC is exploratory. Novel anti-PRLR antibody with no prior efficacy data in AGA. Tight timeline to report by Dec 2026; data may not be available. Low likelihood of numerical improvement.

Early-phase trial with safety primary endpoint; TAHC is exploratory. Novel anti-PRLR mechanism has limited clinical validation. Small sample size increases noise. Primary completion is Dec 31, 2026, leaving little time for data cleaning and reporting. Likelihood of reporting any numerical improvement by that date is low.

Novel anti-PRLR antibody in AGA, Phase 1/2 with safety primary endpoint. TAHC is secondary, not powered. Tight timeline: primary completion Dec 31, 2026, with 178 days left; risk of delay. Unproven mechanism, small sample. However, 'numerical improvement' is a low bar; any increase from baseline could be reported. Intrinsic YES probability ~30%.

Phase 1/2 trial of novel anti-PRLR antibody for AGA with no prior efficacy data. Small sample, recruiting, primary completion Dec 2026 leaves little time for data readout. Any numerical TAHC improvement could occur by chance but mechanism is unproven; most early-stage assets fail. Low probability of clear positive signal.

Phase 1/2 trial with primary safety endpoint; TAHC is secondary. Novel anti-PRLR mechanism unproven in AGA. Small sample, still recruiting, tight timeline to completion. Most early-stage hair loss drugs fail to show numerical improvement.

Phase 1/2 trial with primary endpoint safety, not TAHC. Novel anti-PRLR antibody for AGA, no prior efficacy data. Tight timeline to report numerical TAHC improvement by Dec 2026; high risk of null or insufficient data.

Phase 1/2 trial of novel anti-PRLR antibody for AGA, primarily safety with TAHC as exploratory. Short 6-month timeline to complete and report. High biological uncertainty and early-stage failure risk. Numerical improvement possible but unlikely given lack of prior efficacy data and small sample size.

Phase 1/2 trial of novel anti-PRLR antibody in AGA; primary endpoint is safety, TAHC is exploratory. No prior efficacy data, small sample size, high variability. Numerical improvement possible but far from certain. Intrinsic probability ~25%.

Phase 1/2 AGA trial of anti-PRLR antibody; primary endpoint is safety, but TAHC is a secondary endpoint. Numerical improvement is a low bar, and precedent with HMI-115 anti-PRLR shows hair growth. However, small sample, open-label, and tight timeline to report by Dec 31, 2026, introduce risk. Estimated 60% probability.

Phase 1/2 trial primarily for safety, small sample, novel anti-PRLR mechanism with no prior AGA efficacy data. Numerical TAHC improvement is a low bar but still highly uncertain in early development. Likelihood of any positive signal by Dec 2026 estimated at ~25%.

Phase 1/2 trial primarily assesses safety, small sample size, novel anti-PRLR mechanism with no prior efficacy data. TAHC reporting not guaranteed; numerical improvement possible but unlikely given early stage and unproven target.

Phase 1/2 trial of novel anti-PRLR antibody in AGA. Primary endpoint is safety, TAHC is secondary. Limited prior clinical data for mechanism. Recruiting status and 6-month timeline to completion add uncertainty. Modest chance of numerical improvement, estimated ~30%.

Phase 1/2 trial primarily for safety; TAHC is an exploratory endpoint. Novel anti-PRLR mechanism lacks human efficacy data in AGA. Small sample, not powered for efficacy. Numerical improvement is a low bar, but early biologics often fail to show any signal. Preclinical rationale is limited. Probability of any TAHC improvement is low.

Phase 1/2 safety trial with no prior human efficacy data for anti-PRLR antibody in AGA. Numerical TAHC improvement is possible but unlikely given small sample, novel target, and early stage. Most Phase 1 drugs fail to show any efficacy signal.

Phase 1/2 trial with TAHC as secondary endpoint. Numerical improvement is a low bar; any positive change from baseline qualifies. Company likely to report some efficacy signal if trial completes on time. Novel anti-PRLR target adds uncertainty, but chance of reporting any numerical improvement is moderately high.

Phase 1/2 anti-PRLR antibody still recruiting with only 174 days to primary completion. TAHC improvement typically requires 3-6 months treatment duration; patients enrolled now may not have sufficient exposure by Dec 2026. Novel mechanism with no prior human efficacy data adds uncertainty. However, early-phase hair count signals can emerge, and the trial is designed to capture TAHC, giving some nonzero chance of a numerical improvement being reported.

Phase 1/2 anti-PRLR antibody in AGA with a novel, unproven mechanism. Trial still recruiting with only 175 days to primary completion, creating significant timeline risk for enrollment and data readout. TAHC requires measurable hair growth over months; even numerical improvement demands completed dosing and follow-up. However, 'numerical improvement' is a low bar versus statistical significance, and Absci's AI-designed antibody platform may have differentiated affinity. Net odds remain low but above current market price.

Phase 1/2 anti-PRLR antibody in AGA with safety as protocol primary endpoint; TAHC is secondary and novel mechanism lacks human efficacy precedent. Trial still recruiting with only 175 days to primary completion, creating timeline risk for enrollment and data readout. Early-phase hair count endpoints are noisy and may not show numerical improvement. Sponsor is small-cap biotech with limited operational track record.

Phase 1/2 anti-PRLR antibody in AGA, still recruiting with 175 days to primary completion. Market asks for numerical TAHC improvement (low bar vs statistical significance), but timeline is tight: patients enrolled now may not have sufficient treatment duration for measurable hair growth by Dec 31. Some early-enrolled patients could yield interim TAHC data. Novel mechanism with limited human proof-of-concept adds uncertainty. Probability of reporting any numerical improvement by deadline is modest but well above current market implied odds.

Phase 1/2 anti-PRLR antibody in AGA with no prior human efficacy data. Trial still recruiting with only 175 days to primary completion; TAHC endpoints typically require 6+ months dosing plus measurement. Protocol primary endpoint is safety, not efficacy. Novel mechanism, tight timeline, and recruiting status make numerical TAHC improvement by Dec 2026 unlikely.

Phase 1/2 anti-PRLR antibody with no prior human efficacy data. Trial still recruiting with only 176 days to primary completion. AGA hair-count endpoints typically require 12-24 weeks treatment plus follow-up, making a TAHC readout by Dec 2026 very unlikely. Protocol primary endpoint is safety, not TAHC. Small chance of interim efficacy signal from early cohorts, but timeline and mechanism risk dominate.

Phase 1/2 anti-PRLR antibody in AGA, still recruiting with only 176 days to primary completion. Hair growth endpoints like TAHC typically require 3-6 months of treatment to show measurable change. If patients are still being enrolled, many may not have sufficient treatment duration by Dec 2026. Novel mechanism with no prior efficacy data. 'Numerical improvement' is a low bar, but timeline and recruiting status create substantial risk of no observable TAHC increase.

Phase 1/2 anti-PRLR antibody in AGA is early-stage with a novel mechanism. Trial is still recruiting with only 176 days to primary completion. Hair count endpoints typically require 6+ months of treatment to show measurable change, and reporting TAHC data by Dec 2026 is uncertain given enrollment timeline. Safety is the protocol primary endpoint; TAHC is secondary and may not be prioritized in initial readout.

Phase 1/2 trial still recruiting with 176 days to primary completion. Protocol primary endpoint is safety/tolerability, not TAHC. AGA hair count trials typically need 6+ months treatment duration per patient to show measurable change; if enrollment is ongoing, later-enrolled patients may lack sufficient exposure by Dec 2026. Anti-PRLR is a novel, first-in-class mechanism with no prior clinical efficacy data. Risk of no numerical TAHC improvement being reported in time is substantial.

Phase 1/2 anti-PRLR antibody in AGA, still recruiting with 177 days to primary completion. Hair growth endpoints require months of treatment exposure, and no prior human efficacy data exists for this novel mechanism. However, the bar is numerical TAHC improvement, not statistical significance, which is achievable in early-phase efficacy cohorts if biologically active. Execution and timeline risk are substantial but not overwhelming.

Trial is still recruiting in July 2026 with Dec 2026 primary completion—only ~177 days remain. Hair growth endpoints like TAHC typically require 16-24 weeks of treatment plus assessment, making timely readout unlikely if enrollment isn't complete. Protocol primary endpoint is safety, not TAHC. ABS-201 is a novel anti-PRLR antibody with no prior human efficacy data, adding mechanistic uncertainty. Tight timeline and recruiting status significantly reduce odds of numerical TAHC improvement being reported by year-end.

Anti-PRLR antibody is a novel mechanism for AGA with limited clinical validation. The bar is only numerical TAHC improvement (not statistical significance), which is low—placebo-like trends can qualify. However, the trial is still recruiting with 177 days to primary completion, creating real readout-timing risk. Small Phase 1/2 sample and dose-finding uncertainty further temper odds. Net: modestly favorable but far below market-implied 94%.

Phase 1/2 anti-PRLR antibody in AGA with no prior human efficacy data. Trial still recruiting with only 177 days to primary completion, creating enrollment and data-readout timeline risk. Protocol primary endpoint is safety, not TAHC; market requires numerical hair count improvement which is uncertain for a novel mechanism. Low bar (any numerical increase) helps, but execution risk and biological uncertainty remain substantial.

Phase 1/2 anti-PRLR antibody in AGA with no prior human efficacy data. Protocol primary endpoint is safety, not TAHC; hair count is exploratory. Trial still recruiting with only 177 days to primary completion—operational risk that data won't be reported by deadline is high. Novel mechanism, small biotech sponsor, and low bar (numerical improvement only) cut both ways, but disclosure timing and efficacy uncertainty dominate.

ABS-201 targets PRLR, a novel and incompletely validated mechanism in AGA. This Phase 1/2 trial's protocol primary endpoint is safety/tolerability, with TAHC as a secondary/exploratory measure. The trial is still recruiting with 177 days to estimated primary completion, raising risk that efficacy data won't be reported by Dec 31, 2026. Early-phase hair count endpoints in small populations are noisy, and numerical improvement (not significance) is a lower bar but still uncertain for an unproven target.

Phase 1/2 anti-PRLR antibody in AGA with no prior human efficacy data. Trial still recruiting with only 178 days to primary completion; AGA hair count endpoints typically require 6+ months treatment before measurable TAHC changes. 'Numerical improvement' is a low bar, but tight timeline, novel mechanism, and early-phase design create substantial uncertainty. Sponsor is a small AI-discovery biotech with limited clinical track record.

Phase 1/2 anti-PRLR antibody with novel mechanism in AGA; primary endpoint is safety/tolerability, not TAHC. Trial still recruiting with 178 days to primary completion. Hair growth endpoints require months of treatment and follow-up, making timely TAHC readout uncertain. Numerical improvement is a low bar but unproven mechanism and early-phase design limit confidence in efficacy signal by Dec 2026.

ABS-201 targets PRLR, a novel and clinically unproven mechanism for AGA. This Phase 1/2 trial's protocol primary endpoint is safety/tolerability, not efficacy. With 178 days to primary completion and still recruiting, treatment duration may be insufficient for measurable TAHC improvement, which typically requires 6-12 months. Small early-phase sample sizes and lack of prior clinical hair-growth data for anti-PRLR antibodies increase uncertainty about achieving numerical TAHC improvement by Dec 2026.

Phase 1/2 anti-PRLR antibody in AGA is still recruiting with only 178 days to primary completion. Reporting numerical TAHC improvement requires completing enrollment, dosing, follow-up, and data analysis by Dec 31, 2026—a tight timeline. Novel mechanism with no prior human efficacy data adds significant uncertainty. Execution and disclosure risk are high for a small biotech.

ABS-201 is a novel anti-PRLR antibody in early Phase 1/2 with no prior human efficacy data. Trial is still recruiting with only 179 days to primary completion, limiting treatment duration for measurable TAHC improvement. Hair growth cycles span months, so even numerical (non-statistical) improvement may be hard to demonstrate by Dec 2026 if enrollment is delayed. Sponsor is small biotech with execution risk.

ABS-201 is a first-in-class anti-PRLR antibody with no prior human efficacy data in AGA. The trial is still recruiting in July 2026 with primary completion in Dec 2026, leaving insufficient follow-up for many patients to show measurable TAHC change given hair growth cycles of 3-6+ months. The protocol primary endpoint is safety, not TAHC, suggesting efficacy reporting may be secondary or exploratory. Numerical improvement is a low bar, but timing and novel mechanism risk weigh heavily.

Phase 1/2 anti-PRLR antibody in AGA, still recruiting with only 179 days to primary completion. Novel mechanism with no prior human efficacy data. Numerical TAHC improvement is a low bar, but enrollment delays, limited treatment-and-observation window, and uncertain biological rationale for PRLR blockade driving measurable hair growth in early-phase testing all lower intrinsic odds. Safety/PK is the protocol primary endpoint; efficacy signal is exploratory and not guaranteed.

Phase 1/2 anti-PRLR antibody in AGA with no prior human efficacy data. Novel mechanism (prolactin receptor blockade) must translate preclinical signals to humans. Trial still recruiting with only 179 days to primary completion—significant timeline risk for dosing, follow-up, and data reporting by Dec 2026. 'Numerical improvement' is a low bar, but early-phase AGA trials often fail to show even marginal TAHC gains, and operational delay risk is high for a small sponsor.

Phase 1/2 anti-PRLR antibody in AGA with only 180 days to primary completion while still recruiting. Hair cycle biology typically requires 16-24 weeks of treatment to observe TAHC changes, so treatment duration may be insufficient for many subjects by Dec 2026. Novel mechanism with limited clinical precedent. However, 'numerical improvement' is a low efficacy bar requiring only any upward trend, not statistical significance. Sponsor is small biotech with execution risk. Balanced risk between insufficient treatment duration and low efficacy threshold.

Phase 1/2 trial of a novel anti-PRLR antibody still recruiting with only 181 days to primary completion. AGA hair growth endpoints like TAHC typically require months of treatment to show measurable change. Late recruitment status raises risk that insufficient patient data accumulates by Dec 2026. Protocol primary endpoint is safety, not TAHC. Novel mechanism with limited clinical precedent adds efficacy uncertainty. The bar is only numerical improvement, not significance, but timeline risk is substantial.

Phase 1/2 anti-PRLR antibody in AGA is still recruiting with only 182 days to primary completion. TAHC improvement typically requires 4-6 months of treatment per subject, so enrolling, dosing, and capturing sufficient efficacy data by Dec 2026 is operationally tight. Novel prolactin-receptor mechanism lacks human efficacy precedent, adding biological uncertainty. Safety-first design suggests TAHC may be secondary/exploratory and not guaranteed to be reported numerically by year-end.

Phase 1/2 anti-PRLR antibody still recruiting in July 2026 with Dec 2026 primary completion. Hair growth endpoints require months of treatment to show measurable TAHC changes; late-enrolled patients won't have sufficient exposure. Protocol primary endpoint is safety/tolerability, not efficacy. Novel mechanism with no prior clinical hair-growth proof. 'Numerical improvement' is a low bar but timeline risk and recruiting status make timely positive TAHC reporting uncertain.

Early Phase 1/2 anti-PRLR antibody with novel, unproven mechanism in AGA. Trial still recruiting with only 183 days to primary completion; hair growth endpoints like TAHC require sufficient treatment duration, creating timeline risk for later cohorts. Protocol primary endpoint is safety, not efficacy. Small sample size and dose-finding nature reduce likelihood of clear numerical TAHC improvement by Dec 2026.

Phase 1/2 anti-PRLR antibody with no prior human efficacy data; protocol primary endpoint is safety, not TAHC. Trial still recruiting in June 2026 with Dec 2026 completion—patients enrolled late may lack sufficient treatment duration for measurable hair count change. Novel mechanism is biologically plausible but early-phase efficacy signal is inherently uncertain and timing risk is high.

Phase 1/2 trial primarily evaluating safety; TAHC is a secondary measure. Anti-PRLR is a novel, clinically unvalidated mechanism for AGA. Primary completion is Dec 2026, making reporting of efficacy data by that exact date tight. Modest chance of numerical improvement given unproven target and timeline risk.

Anti-PRLR antibody is a novel, clinically unvalidated mechanism for AGA. Protocol primary endpoint is safety/tolerability, not TAHC efficacy. Phase 1/2 trials often lack powered efficacy readouts; TAHC improvement is secondary/exploratory. Limited prior clinical data on PRLR inhibition for hair growth reduces confidence in efficacy signal. 190 days to completion adds timeline risk for reporting.

Phase 1/2 trial primarily targets safety; TAHC is a secondary efficacy endpoint. Early-phase hair growth data is often noisy and underpowered. While ABS-201 has a novel mechanism, numerical improvement in a small cohort is uncertain given the short timeline and recruiting status.

Phase 1/2 trial in AGA with primary endpoint TAHC. Anti-PRLR mechanism is novel but unproven in hair growth. Early-phase efficacy signals are often noisy. Small sample sizes and short duration may limit statistical power for numerical improvement. Safety is primary, efficacy secondary. High risk of null or negligible TAHC change.

Phase 1/2 trial primarily powered for safety. TAHC is a secondary/exploratory efficacy endpoint in early-stage AGA studies. Anti-PRLR mechanism is novel with limited prior clinical proof-of-concept for hair regrowth. High risk of null or negligible numerical improvement in small cohort by year-end.

Phase 1/2 trial for ABS-201 in AGA. Primary endpoint is safety, but market resolves on numerical TAHC improvement. Anti-PRLR mechanism has biological plausibility. Early-phase hair count data often shows numerical gains due to natural variation or mild efficacy, even if not statistically significant. High probability of *some* numerical improvement.

ABS-201 targets PRLR, a novel mechanism for AGA with strong preclinical rationale. Phase 1/2 trials in early-stage AGA often show numerical TAHC improvements due to low baseline variability and drug activity. However, small sample sizes and short duration create volatility. Safety is primary, but efficacy signals are likely detectable numerically even if not statistically powered.

ABS-201 targets PRLR, a novel mechanism for AGA with plausible biological rationale. Phase 1/2 trials in early-stage hair loss often show numerical TAHC improvements due to low baseline variability and placebo effects. However, safety signals or lack of efficacy could hinder results. The 'numerical improvement' bar is low, favoring YES, but clinical risk remains significant given the early phase and recruiting status.

ABS-201 targets PRLR, a novel mechanism for AGA with strong preclinical rationale. Phase 1/2 trials in early-stage indications often show numerical hair count improvements due to placebo effects and natural variability, even if statistical significance is not met. The bar for 'numerical improvement' is low compared to statistical significance.

ABS-201 targets PRLR, a novel mechanism for AGA. Phase 1/2 trials in early-stage hair loss often show numerical TAHC improvements due to low baseline variability and placebo effects. While safety is the primary endpoint, numerical efficacy data is typically reported. Absci's platform has precedent in generating binders, but clinical translation in AGA is unproven. Moderate probability of numerical improvement, though statistical significance is not required by the question.

ABS-201 targets PRLR, a novel mechanism for AGA with preclinical promise. Phase 1/2 trials in early-stage hair loss often show numerical TAHC improvements due to placebo variability and natural fluctuation. Absci's AI-driven antibody design may optimize binding. However, small sample sizes and short duration increase noise. Numerical improvement is a low bar compared to statistical significance, favoring a positive outcome despite clinical uncertainty.

ABS-201 targets PRLR, a novel mechanism for AGA with plausible biological rationale. Phase 1/2 trials in early-stage hair loss often show numerical TAHC improvements due to placebo effects and natural variation, even if statistical significance is missed. The bar is 'numerical improvement,' not statistical significance, making YES likely despite early stage.

ABS-201 targets PRLR, a novel mechanism for AGA with strong preclinical rationale for hair growth. Phase 1/2 trials in this indication typically show numerical TAHC improvements vs baseline due to natural variability and drug effect. Safety is primary, but numerical TAHC gain is highly probable in early-stage data readouts.

ABS-201 targets PRLR, a novel mechanism for AGA with plausible biological rationale. Phase 1/2 trials in early-stage indications often show numerical improvements in hair count due to placebo effects or mild efficacy. While safety is the primary endpoint, numerical TAHC improvement is a low bar compared to statistical significance. Absci's platform has prior success, boosting likelihood of some positive signal, though clinical meaningfulness is unproven.

The trial is only in Phase 1/2 and still recruiting, so no efficacy data exist. The endpoint (TAHC) requires a demonstrable numeric hair‑count increase, which anti‑PRLR has no established mechanism in AGA. Early‑stage biologics for hair loss historically have low success rates, suggesting a modest intrinsic chance (~15‑20 %).

Phase 1/2 recruiting trial with primary focus on safety, not efficacy. Target Area Hair Count improvement is a secondary, unproven endpoint for an anti‑PRLR antibody in AGA. Early‑stage data and lack of prior efficacy signals suggest modest chance of a measurable TAHC gain by Dec 2026.

Phase 1/2 trial still recruiting with no efficacy data; primary endpoint is a quantitative hair‑count improvement, which early‑phase studies rarely power for. Anti‑PRLR mechanism is unproven in AGA, and the Dec 2026 deadline leaves limited time to enroll and analyze. Intrinsic chance of a measurable TAHC gain is modest, around 30%.

Phase 1/2 trial is still recruiting and its primary endpoint is safety/tolerability, not hair‑count efficacy. No efficacy data exist yet, and early‑stage anti‑PRLR antibodies have limited precedent in AGA. Thus the intrinsic chance of reporting a numerical TAHC improvement by Dec 2026 is low (~8%).

Phase 1/2 trial still recruiting, primary endpoint is safety, not efficacy; no prior data on anti‑PRLR in AGA; hair‑count improvements are hard to achieve; high operational risk and short timeline to Dec 2026 suggest low intrinsic chance (~25%).

The trial is only Phase 1/2 and still recruiting, with primary completion at the end of 2026. No prior efficacy data for anti‑PRLR in AGA exist, and early‑phase hair‑count endpoints are difficult to meet. Consequently the intrinsic chance of a meaningful TAHC improvement is modest, likely around 20 %.

Phase 1/2 recruiting trial, primary endpoint is safety/tolerability, not efficacy. Anti‑PRLR is untested in AGA, no prior data, and market requires a numerical TAHC gain by end‑2026. Early‑stage biology and execution risk make a positive outcome unlikely.

Phase 1/2 recruiting trial with no efficacy data yet; primary endpoint is safety, while market requires a numerical TAHC improvement. Early‑stage anti‑PRLR antibody lacks prior proof‑of‑concept, making a measurable hair‑count gain by Dec 2026 unlikely.

Phase 1/2 recruiting anti‑PRLR antibody has no prior AGA data; primary endpoint is safety, not hair count; TAHC improvement is unproven and timeline short; early‑stage novel target suggests low likelihood of a statistically meaningful numeric gain by Dec 2026.

The trial is Phase 1/2 and still recruiting; its primary endpoint is safety/tolerability, while the market requires a quantitative TAHC improvement. No efficacy data have been disclosed and only ~177 days remain to primary completion, limiting the chance of a measurable hair‑count gain by Dec 2026.

Phase 1/2 trial is still recruiting and primary focus is safety/tolerability; efficacy (TAHC) has no prior data for anti‑PRLR in AGA, making a numerical hair‑count improvement by end‑2026 unlikely.

Phase 1/2 trial is still recruiting and its protocol primary endpoint is safety/tolerability, not efficacy. The market‑required endpoint (TAHC) has no early data. Anti‑PRLR antibodies have no proven benefit in AGA, and the deadline (Dec 2026) leaves limited time for enrollment and readout. Consequently, intrinsic chance of a numerical TAHC improvement is low.

The trial is early Phase 1/2, still recruiting, and its primary endpoint is safety/tolerability, not efficacy. The market question demands a quantitative improvement in hair count, yet no prior efficacy data for anti‑PRLR in AGA exist, making a positive result by Dec 2026 unlikely.

Phase 1/2 recruiting anti‑PRLR antibody in AGA; primary endpoint is numeric TAHC improvement but no data yet. Early‑stage biologic with unproven mechanism, high failure risk, and limited time to complete trial suggests low chance of reporting a meaningful improvement by Dec 2026.

Trial is recruiting, Phase 1/2, with safety as primary endpoint; efficacy (TAHC) is not yet measured and early anti‑PRLR in AGA lacks precedent, making a numerical hair count improvement by 2026 unlikely (~20% chance).

Phase 1/2 recruiting with no prior human data for anti‑PRLR in AGA, primary endpoint requires a measurable hair‑count increase which is hard to demonstrate early. Safety‑focused protocol, short timeline to Dec 2026 and operational risk lower the intrinsic chance of a positive TAHC result to roughly 20%.

The trial is only in Phase 1/2 and still recruiting, so no efficacy data exist. Anti-PRLR is a novel target for AGA with limited precedent, making a clear hair‑count improvement by Dec 2026 unlikely. Early‑stage safety focus and the tight deadline further reduce confidence in a positive numeric outcome.

The trial is Phase 1/2 and still recruiting, with a primary safety/tolerability endpoint. No efficacy data are available yet, and the market requires a numerical TAHC improvement by Dec 2026, making a positive result unlikely.

The trial is only in Phase 1/2 and still recruiting, with no efficacy data yet. The primary endpoint (TAHC improvement) is a quantitative efficacy readout that early‑stage anti‑PRLR antibodies have not demonstrated in AGA. Novel mechanism, limited preclinical evidence, and a short timeline to Dec 2026 increase uncertainty, making a positive outcome unlikely.

The study is only in Phase 1/2 and still recruiting, so no efficacy data exist. The primary endpoint listed is safety, while the market asks for a numerical TAHC improvement, a higher‑bar efficacy readout that early‑stage anti‑PRLR antibodies have not yet demonstrated in AGA. Lack of prior data and early development increase uncertainty, suggesting a low intrinsic chance of a positive result.

The trial is only in Phase 1/2 and still recruiting, so no efficacy data exist. The primary endpoint is safety, while the market asks for a numerical TAHC improvement, a hard endpoint for early-stage AGA studies. Without prior proof of concept, the chance of a positive hair-count result by the end of 2026 is low.

Phase 1/2 trial still recruiting with no efficacy data; primary endpoint is safety, while market requires a numerical TAHC improvement. Anti‑PRLR is unproven in AGA, and early‑phase studies often fail to show efficacy, making the chance of a positive result modest.

The trial is early‑phase (Phase 1/2) and still recruiting, with safety/tolerability as the protocol primary endpoint. No efficacy data are expected before Dec 2026, and the market requires a numeric TAHC gain. Given the lack of data and early stage, the intrinsic chance of a positive TAHC result is low (~20%).

The trial is only in Phase 1/2 and still recruiting, with no efficacy data yet. The primary regulatory endpoint is safety, while the market asks for a numerical TAHC improvement, a challenging efficacy readout for a novel anti‑PRLR antibody. Early‑stage uncertainty and lack of prior signal suggest a low chance of meeting the numeric hair‑count endpoint by the end of 2026.

Early Phase 1/2 recruiting trial with no prior data; anti‑PRLR antibody for AGA is unproven. Primary endpoint (TAHC) requires a measurable hair count increase by end‑2026, a challenging efficacy bar for a first‑in‑class biologic. High operational risk and limited time to generate and read out data lower the intrinsic chance of a positive result.

Phase 1/2 early‑stage anti‑PRLR antibody, still recruiting with primary completion Dec 2026. Primary endpoint is safety/tolerability, while market requires a numeric TAHC gain. No efficacy data exist, mechanism is unproven in AGA, and operational risk of enrollment delays is high, making a positive outcome unlikely.

Phase 1/2 recruiting trial with no efficacy data yet; primary endpoint is safety, while market requires a numerical TAHC improvement. Anti‑PRLR is unproven in AGA, and early‑stage execution risk is high. Given the timeline to Dec 2026, the intrinsic chance of reporting a meaningful hair‑count gain is low.

Phase 1/2 is early and still recruiting, so no efficacy data exist. The anti‑PRLR antibody for AGA is mechanistically unproven, and the trial’s primary endpoint is safety, not the required TAHC metric. Achieving a statistically measurable hair‑count improvement by Dec 2026 is therefore uncertain, giving roughly a 30% chance of a positive result.

Early‑stage Phase 1/2 trial still recruiting with primary safety endpoint; efficacy (TAHC) not yet demonstrated and no prior data on anti‑PRLR in AGA. Market requires numeric hair count improvement by end‑2026, a high bar for an unproven antibody, making intrinsic yes odds low (~15%).

Phase 1/2 early‑stage, still recruiting, no efficacy data; anti‑PRLR is novel for AGA with no precedent. Primary endpoint is safety, while market requires a numerical TAHC improvement, making a positive result by end‑2026 unlikely.

Phase 1/2 trial is still recruiting with no efficacy data; the primary endpoint is TAHC improvement but the protocol emphasizes safety; anti‑PRLR is unproven in AGA; early stage and short timeline to Dec 2026 make a meaningful hair‑count gain unlikely.

Phase 1/2 anti-PRLR antibody for AGA with safety/tolerability as protocol primary endpoint, not TAHC efficacy. Market requires TAHC improvement by Dec 31, 2026 with only 174 days remaining. Early-stage biologics rarely show meaningful hair count changes in first-in-human studies. Small sample size, no prior clinical data for ABS-201, and sponsor has limited dermatology track record. High disclosure risk if only safety data reported.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is secondary/exploratory. Anti-PRLR mechanism in AGA is novel but unvalidated clinically. Only 175 days to completion with no prior human efficacy data disclosed. Low probability of meaningful TAHC improvement reported by Dec 2026.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is unproven clinically. 175 days to completion with recruiting status means limited data generation time. No prior ABS-201 human efficacy data disclosed. High disclosure risk: Absci may report safety/PK only without meaningful TAHC numbers by year-end. Market requires numerical TAHC improvement, not just any data.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is novel but unproven; no prior human efficacy data disclosed. 175 days to completion with safety-focused primary endpoint makes meaningful TAHC readout unlikely by Dec 2026. Small N expected in Phase 1/2. High disclosure risk if data is immature.

Phase 1/2 safety-tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is novel but unvalidated. 175 days to completion with no interim efficacy readout disclosed. High disclosure risk: Absci may report safety/PK without TAHC data by year-end. Low probability of meaningful TAHC improvement from small early-stage study.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is secondary/exploratory. No prior human efficacy data for ABS-201 disclosed. 176 days to completion with recruitment ongoing leaves limited time for enrollment, treatment, and analysis. Anti-PRLR mechanism in AGA is novel but unvalidated in humans. Low probability of meaningful TAHC data disclosure by year-end.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is exploratory. No prior human efficacy data for ABS-201 disclosed. 176 days to completion with recruiting status suggests limited time for enrollment, treatment, and data analysis. Hair growth trials typically need 24+ weeks. High disclosure risk: sponsor may report safety/PK only without TAHC improvement. Market requires numerical TAHC improvement by Dec 31, 2026 — unlikely for early-stage asset.

Phase 1/2 safety-first trial with primary endpoint formally set as safety/tolerability, not efficacy. TAHC is a secondary/exploratory endpoint. Only 176 days remain to completion with trial still recruiting—underpowered for meaningful hair count data. Anti-PRLR mechanism in AGA is novel but unvalidated clinically. Low prior probability of positive efficacy readout in small early-stage study by year-end.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is secondary/exploratory. No prior clinical data for ABS-201 in AGA. 176 days to completion with recruiting status suggests limited time for enrollment, dosing, and hair growth assessment. Anti-PRLR mechanism is novel and unvalidated in AGA. High disclosure risk: sponsor may report safety/PK only without meaningful TAHC data by year-end.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. 177 days to completion with no interim data disclosed. Anti-PRLR mechanism in AGA is novel but unvalidated. Low probability of meaningful TAHC readout by year-end given primary focus on safety, small sample size, and early phase. Hair growth trials typically need 6+ months treatment plus analysis time.

Phase 1/2 safety-first design with primary endpoint of tolerability, not efficacy. TAHC is exploratory/secondary. No prior clinical data for ABS-201 in AGA. 177 days to completion with trial still recruiting—high risk of incomplete readout by Dec 31. Anti-PRLR mechanism in AGA is novel but unvalidated. Disclosure risk: sponsor may report safety/PK top-line without efficacy detail.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is secondary/exploratory. No prior human efficacy data for ABS-201 in AGA. Anti-PRLR mechanism is unproven for hair growth. 177 days to completion; early-stage readouts rarely show statistically meaningful TAHC changes. High disclosure risk if only safety data reported.

Phase 1/2 safety trial with 177 days to completion. Primary protocol endpoint is safety/tolerability, not efficacy. TAHC is a secondary/exploratory endpoint. Early-stage antibody in AGA lacks prior human efficacy data. High disclosure risk: sponsor may report safety/PK top-line without TAHC data by year-end. Market requires explicit numerical TAHC improvement, unlikely in small Phase 1/2 safety cohort.

Phase 1/2 trial with safety/tolerability as protocol endpoint, not TAHC efficacy. Market requires numerical TAHC improvement by Dec 31, 2026, but primary completion is same date with 177 days remaining. Early-stage biologics in AGA rarely show meaningful hair count changes in initial safety-focused cohorts. No prior clinical data for ABS-201 disclosed. High disclosure risk: sponsor may report safety/PK only without efficacy readout by deadline.

Phase 1/2 trial with safety/tolerability as protocol primary endpoint, not TAHC efficacy. Market requires TAHC improvement by Dec 31, 2026 with only 177 days remaining. Anti-PRLR mechanism in AGA is novel but unvalidated clinically. No prior human efficacy data disclosed. High disclosure risk: Absci may report safety/PK without TAHC data, or data may be immature. Small sample size typical for Phase 1/2 limits power to detect hair count changes.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is unproven clinically. Only ~6 months to readout with no prior human efficacy data disclosed. High disclosure risk: sponsor may report safety/PK only without meaningful TAHC numbers. Market requires numerical TAHC improvement by Dec 31, 2026—unlikely for early-stage asset with safety-primary design.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. 178 days to completion; anti-PRLR mechanism in AGA unproven. No prior clinical data disclosed. High disclosure risk: sponsor may report safety/PK only without numerical TAHC. Market requires specific TAHC improvement by year-end, unlikely for early-phase readout.

Phase 1/2 trial with safety/tolerability as protocol endpoint, not efficacy. Market requires TAHC improvement by Dec 31, 2026—only 178 days away. Anti-PRLR mechanism in AGA is novel but unvalidated clinically. No prior human efficacy data disclosed. Early-phase studies rarely report meaningful efficacy endpoints on time; primary completion often means safety database lock, not published TAHC results. High disclosure risk: sponsor may report safety/PK only.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is secondary/exploratory. No prior clinical data for ABS-201 in AGA. Anti-PRLR mechanism is novel and unvalidated for hair growth. 178 days to completion with recruiting status means limited time to enroll, treat, and read out efficacy data by Dec 31, 2026. High disclosure risk: sponsor may report safety/PK only without TAHC numbers. Market requires explicit numerical TAHC improvement, which is unlikely in a small early-stage study.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. No prior ABS-201 human efficacy data disclosed. 179 days to completion; hair growth trials typically need 6+ months for measurable TAHC. High disclosure risk: sponsor may report safety/PK only without numerical TAHC. Market conflates safety trial with efficacy readout.

Phase 1/2 trial with safety primary endpoint; TAHC is secondary/exploratory. No prior ABS-201 human efficacy data disclosed. 179 days to completion with recruiting status suggests limited time for enrollment, treatment, and analysis. Hair growth trials typically need 24+ weeks. High disclosure risk: Absci may report safety/PK top-line without TAHC numerical improvement by year-end. Market conflates safety readout with efficacy data.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. No prior human efficacy data for ABS-201 in AGA. Anti-PRLR mechanism unproven for hair growth. 179 days to completion; early-stage readout unlikely to show statistically meaningful TAHC improvement. High disclosure risk if only safety reported.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is novel but unvalidated clinically. 179 days to completion with no prior human efficacy data disclosed. High disclosure risk: Absci may report safety/PK only without meaningful TAHC numbers by year-end. Market requires numerical TAHC improvement, a higher bar than typical early-phase readouts.

Phase 1/2 safety-tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is novel but unvalidated. 180 days to completion with recruiting status means limited data generation time. No prior clinical proof-of-concept disclosed. High disclosure risk: Absci may report safety/PK without meaningful TAHC data by year-end. Market implies near-certainty of positive TAHC readout, which is unsupported by trial design.

Phase 1/2 safety/tolerability trial with TAHC as exploratory, not powered endpoint. Anti-PRLR mechanism in AGA is novel but unvalidated. 181 days to completion with recruiting status means limited data readout time. High disclosure risk: Absci may report safety/PK without definitive TAHC numbers by year-end. Historical hair-growth trials show high placebo response and frequent Phase 2 failures. Market requires numerical TAHC improvement, not just safety clearance.

Phase 1/2 safety-first trial with primary endpoint of safety/tolerability, not efficacy. TAHC is a secondary/exploratory endpoint. Anti-PRLR mechanism in AGA is novel but unvalidated clinically. Only 182 days to completion; hair growth trials typically need 6+ months for measurable TAHC change. Small early-stage study likely underpowered for meaningful efficacy signal. High disclosure risk: Absci may report safety/PK without specific TAHC data by year-end.

Phase 1/2 trial with safety/tolerability primary endpoint, not TAHC efficacy. Market requires TAHC improvement by Dec 2026, but primary completion is Dec 2026 with only 182 days remaining. Anti-PRLR mechanism in AGA is novel with no prior human efficacy data. High probability trial completes safety readout without meaningful TAHC data disclosed by year-end. Sponsor may not report efficacy secondary endpoint in initial topline.

Phase 1/2 safety-first design with TAHC as exploratory, not powered endpoint. No prior ABS-201 human efficacy data disclosed. 183 days to completion with recruitment ongoing creates execution risk. Anti-PRLR mechanism in AGA is novel but unvalidated. Safety endpoint focus means TAHC may not be rigorously measured or reported numerically by year-end. High disclosure risk if data immature.

Phase 1/2 trial still recruiting with ~6 months to primary completion. Primary endpoint is safety, not efficacy. Hair count data requires months of treatment and follow-up, making a TAHC readout by year-end operationally tight. No prior human efficacy data for anti-PRLR in AGA. Low probability of reported numerical improvement.

Phase 1/2 study with a safety-primary protocol, not powered for efficacy. Still recruiting with only 185 days to primary completion—insufficient time for typical 24-week AGA treatment, hair-count measurement, and analysis. Novel anti-PRLR mechanism lacks human clinical validation. High risk that only safety/PK data are reported by year-end, with no numerical TAHC improvement disclosed.

Phase 1/2 study with safety/tolerability as protocol primary endpoint, implying small cohort and limited efficacy disclosure obligation. Still recruiting with only 190 days to primary completion; insufficient time to enroll, treat for hair-cycle duration, and report TAHC. Novel anti-PRLR antibody lacks prior human AGA efficacy data in provided fields. Numerical improvement bar is low, but operational execution risk and disclosure timing by Dec 31 are high.

Phase 1/2 with SAFETY as protocol primary endpoint, not efficacy. Trial still recruiting with only 174 days to primary completion - tight for dosing and follow-up to generate TAHC data. Anti-PRLR mechanism in AGA is novel and unvalidated; most AGA drugs target androgens. No prior ABS-201 efficacy data. Endpoint mismatch (safety protocol vs TAHC market question) increases disclosure risk - trial may complete without meaningful hair count readout. Some small chance of preliminary TAHC signal reported as secondary.

Phase 1/2 anti-PRLR antibody in AGA with novel, unvalidated mechanism. Protocol primary endpoint is safety; TAHC is secondary/exploratory, lowering disclosure risk. Market only requires 'numerical improvement' (low bar, no statistical significance needed). Still recruiting with 175 days to completion - tight but feasible. Prior anti-PRLR hair data limited; base rate for novel-mechanism early-stage dermatology trials showing any positive TAHC signal is modest. Risk of underpowered or negative hair count readout remains material.

Phase 1/2 anti-PRLR antibody in AGA with novel, unvalidated mechanism. Trial is still Recruiting with only 175 days to primary completion—tight for enrollment, dosing, follow-up, and TAHC readout. Protocol primary endpoint is safety/tolerability, not TAHC; efficacy is likely secondary/exploratory. 'Numerical improvement' is a low bar but requires successful execution and any positive signal. Recruiting status, early phase, and novel target create substantial readout and efficacy risk.

Phase 1/2 still RECRUITING with only 175 days to primary completion. Protocol primary endpoint is safety/tolerability, not TAHC. Hair count requires months of follow-up after dosing—very unlikely to complete enrollment, dose, and observe TAHC by Dec 31, 2026. Absci is a small-cap biotech with limited operational bandwidth. Disconnect between protocol endpoint and market question adds disclosure risk.

Endpoint mismatch: protocol primary is safety/Tolerability, market asks for TAHC improvement—likely a secondary/exploratory endpoint. Trial still Recruiting with only 175 days to primary completion, leaving little buffer for enrollment + efficacy readout. AGA efficacy typically needs 3-6+ months, so data timing is risky. 'Numerical improvement' is a low bar, but the trial may not report efficacy by Dec 31, 2026 given phase and operational status. Anti-PRLR mechanism has limited prior clinical validation in AGA.

Phase 1/2 with safety as protocol primary endpoint; market asks about TAHC efficacy. Trial still recruiting with ~176 days to deadline—tight for completion and public disclosure. Anti-PRLR is novel for AGA with no prior efficacy data, but 'numerical improvement' is a low bar (vs baseline). Combined probability of completing, reporting, and showing any positive TAHC change estimated ~15%. Market at 1% appears too pessimistic given low efficacy bar.

Phase 1/2 still recruiting; protocol primary is safety/PK, TAHC is likely secondary/exploratory. Novel anti-PRLR mechanism in AGA has uncertain efficacy. Operational risk: ~6 months to primary completion, top-line TAHC reporting timing uncertain. Even modest numerical TAHC improvement in a small early-phase study is far from guaranteed. Market requires reported improvement by Dec 31, 2026, which depends on trial completion and disclosure cadence.

Phase 1/2 anti-PRLR antibody in AGA with novel, unproven mechanism. Protocol primary is safety; TAHC is secondary/exploratory, so efficacy readout not guaranteed. Still recruiting with only 176 days to primary completion in a small early-phase trial. Disclosure risk: Absci may delay efficacy reporting beyond Dec 31, 2026. However, 'numerical improvement' is a low bar and TAHC is typically captured in hair studies even when not primary. Modest base rate reflects mechanism uncertainty and operational risk.

Trial is still Recruiting with ~176 days to primary completion. Phase 1/2 of novel anti-PRLR antibody in AGA; no prior human efficacy data. Protocol primary endpoint is safety/tolerability, not TAHC. Hair count changes require weeks-to-months follow-up after baseline. Recruiting status suggests enrollment may not complete in time, and even interim cohorts would need dosing + observation window before any TAHC readout. Novel mechanism + early phase + tight timeline make numerical TAHC report by Dec 31, 2026 uncertain.

Phase 1/2 with safety/tolerability as protocol primary endpoint, not efficacy. Anti-PRLR is a novel mechanism for AGA with limited prior human data. Trial still Recruiting with only 177 days to Dec 31, 2026 deadline—enrollment, treatment duration (AGA needs months for TAHC changes), and analysis must all fit. Bar is any numerical improvement, which helps, but small Phase 1/2 samples are noisy and disclosure by deadline is uncertain. Modest non-zero chance of a positive efficacy readout, but well below 50%.

Phase 1/2 trial with safety/Tolerability as protocol primary endpoint, not TAHC. TAHC is exploratory/secondary at best. Still recruiting with only 177 days to primary completion—tight for AGA efficacy readout (hair cycle needs 6+ months). Novel anti-PRLR mechanism has no prior human efficacy data in alopecia. Absci's first major clinical asset; small-cap execution risk. Numerical improvement bar is low but enrollment, dosing, and follow-up timing make positive readout by Dec 31, 2026 uncertain.

Phase 1/2 with safety as protocol primary endpoint, not TAHC. Novel anti-PRLR mechanism unvalidated for hair growth. Still recruiting with only 177 days to primary completion—tight execution window. Market asks for 'numerical improvement' (low bar) but disclosure timing risk and small sample size limit confidence. Novel target + early phase + operational risk make 35% reasonable vs market's 94%.

Phase 1/2 trial with primary endpoint of safety/tolerability, not TAHC efficacy. Novel anti-PRLR mechanism with limited prior human efficacy data. Trial still recruiting with only 177 days to completion, creating enrollment/timing risk. Bar is low (numerical improvement, not statistical significance), but Absci disclosure risk and mechanism uncertainty are meaningful. Phase 1/2 novel-mechanism trials show mixed efficacy signals.

Phase 1/2 trial with numerical TAHC endpoint; still recruiting with limited time; early-stage efficacy trials often fail; market price of 94% reflects excessive optimism given AGA mechanism uncertainty and Phase 1 data requirements.

Phase 1/2 still recruiting with 177 days to primary completion. Market question requires numerical TAHC improvement, but protocol primary endpoint is only safety/tolerability. Efficacy endpoints in early-phase hair growth trials are challenging to achieve on tight timelines, especially when the trial hasn't even completed enrollment. Market price at 0.94 seems overly optimistic for a recruiting Phase 1/2.

Protocol's primary endpoint is safety/tolerability, not TAHC improvement. The market question asks for numerical TAHC improvement which is not the trial's stated goal. This Phase 1/2 is still recruiting with 178 days to completion—efficacy data may not be reported by Dec 31. Anti-PRLR mechanism in AGA is speculative with no strong prior validation.

Phase 1/2 trial currently recruiting with 178 days remaining. Primary protocol endpoint is safety/tolerability, not numerical TAHC improvement. Early-phase hair regrowth trials typically require longer follow-up to demonstrate statistical hair count gains. Market misprices this YES at 94% given operational timeline and endpoint mismatch.

Phase 1/2 AGA trial still recruiting with Dec. 31 primary completion target (178 days out). Early-phase novel anti-PRLR mechanism rarely achieves numerical TAHC efficacy within 6 months of trial start. Regulatory approval pathway requires Phase 2 data. Trial status and compressed timeline strongly favor NO.

Phase 1/2 trial primary endpoint is safety, not TAHC efficacy. Market question requires numerical TAHC improvement by Dec 31 2026, but the protocol endpoint focuses on treatment-emergent adverse events. Early-phase trials rarely report efficacy signals as primary outcomes; this mismatch substantially reduces probability of YES resolution.

Phase 1/2 trial for anti-PRLR antibody in AGA requires hard numerical TAHC improvement endpoint. Early phase trials have high historical failure rates. Trial is recruiting with 179 days to completion date, leaving limited time for data reporting. No interim efficacy data provided. Market price of 93.5% appears inflated relative to intrinsic odds given early-stage risk and stringent numerical endpoint requirement.

Phase 1/2 trial's protocol primary endpoint is safety/tolerability only, not TAHC numerical improvement. The market question asks specifically for numerical TAHC improvement by Dec 31 2026, but early-phase trials often don't power efficacy endpoints as primary measures. Even if drug has efficacy, this trial design may not capture the required endpoint readout. Sponsor still recruiting with 179 days to primary completion date adds execution risk. The fundamental mismatch between what the question asks and what the trial is designed to measure reduces intrinsic YES odds despite market pricing...

Protocol primary endpoint is safety/tolerability, not TAHC numerical measurement. Market question requires numerical TAHC improvement, but the trial design may not mandate reporting this by primary completion. Phase 1/2 for hair loss has execution risk and endpoint mismatch between protocol and question creates disclosure uncertainty through Dec 2026.

Phase 1/2 AGA trial in recruiting status with 179 days to completion. Numerical TAHC improvement is required, not just safety endpoints. PRLR mechanism is novel for hair growth. Early-stage execution risk, enrollment challenges, and statistical hurdles on numerical endpoints reduce intrinsic odds. Estimated ~30% probability of meeting TAHC endpoint by Dec 31.

Phase 1/2 AGA trial with safety primary endpoint rather than TAHC efficacy. Early-stage recruiting study with 180 days remaining; TAHC numerical improvement requires specific efficacy measurement not captured by the protocol primary endpoint. Market question likely to resolve NO due to endpoint misalignment.

Phase 1/2 trial with safety primary endpoint, but market asks for numerical TAHC improvement - endpoint mismatch. PRLR antibody mechanism is novel for AGA with no Phase 2 data. Recruiting status with 181 days to complete and report by Dec 31, 2026 creates execution risk. Early-phase trials rarely generate robust numerical efficacy data in this timeframe.

Phase 1/2 trial has safety as protocol primary endpoint, not numerical TAHC improvement. Market question requires TAHC numerical improvement by Dec 31 2026. Trial still recruiting with endpoint misalignment. Achieving efficacy readout within timeline is unlikely given early phase focus on safety/PK.

Protocol primary endpoint is safety/tolerability, not TAHC measurement. Phase 1/2 recruiting with 182 days to primary completion; numerical TAHC data reporting by Dec 31 is unlikely given endpoint misalignment and trial status.

Phase 1/2 anti-PRLR antibody for AGA with primary safety endpoint, currently recruiting. Tight timeline (~6 months to primary completion Dec 31, 2026), early-stage for efficacy endpoint, and PRLR target less validated for hair regrowth vs established mechanisms. Numerical TAHC improvement by year-end is challenging given enrollment and data collection timelines.

Phase 1/2 trial with safety as primary endpoint; question requires numerical TAHC improvement. Early-stage trials rarely demonstrate significant efficacy endpoints. Market mismatch between trial design and question requirement lowers success probability.

Phase 1/2 trial in AGA with primary safety endpoint; efficacy bar of numerical TAHC improvement is high for early-stage work. No prior efficacy data provided, and recruiting status leaves limited time for interim readout by Dec 2026. Anti-PRLR mechanism is promising but unproven in this indication. Probability below 50% due to early phase focus on safety rather than efficacy, though 185 days remaining provides some chance of positive interim data.

Phase 1/2 trial with primary endpoint focused on safety/tolerability, not numerical TAHC efficacy. AGA hair regrowth is challenging; anti-PRLR mechanism is unproven. Trial still recruiting with 190 days to completion—tight timeline for enrollment, treatment, measurement, and reporting. Endpoint mismatch between protocol (safety) and market question (numerical TAHC) creates disclosure risk. Early-stage antibody programs historically struggle on efficacy readouts.